Compare LTC & TYRA Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
| Metric | LTC | TYRA |
|---|---|---|
| Founded | 1992 | 2018 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Real Estate Investment Trusts | Biotechnology: Pharmaceutical Preparations |
| Sector | Real Estate | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 2.0B | 2.0B |
| IPO Year | 1994 | 2021 |
| Metric | LTC | TYRA |
|---|---|---|
| Price | $39.50 | $26.32 |
| Analyst Decision | Hold | Strong Buy |
| Analyst Count | 5 | 11 |
| Target Price | $40.00 | ★ $47.50 |
| AVG Volume (30 Days) | 568.1K | ★ 612.0K |
| Earning Date | 05-06-2026 | 05-06-2026 |
| Dividend Yield | ★ 5.96% | N/A |
| EPS Growth | ★ 23.53 | N/A |
| EPS | ★ 1.05 | N/A |
| Revenue | ★ $262,854,000.00 | N/A |
| Revenue This Year | N/A | N/A |
| Revenue Next Year | N/A | N/A |
| P/E Ratio | $37.60 | ★ N/A |
| Revenue Growth | ★ 25.26 | N/A |
| 52 Week Low | $33.64 | $9.96 |
| 52 Week High | $43.00 | $40.65 |
| Indicator | LTC | TYRA |
|---|---|---|
| Relative Strength Index (RSI) | 46.75 | 34.98 |
| Support Level | $37.82 | $24.77 |
| Resistance Level | $39.65 | $32.82 |
| Average True Range (ATR) | 0.91 | 1.76 |
| MACD | -0.34 | -0.66 |
| Stochastic Oscillator | 32.34 | 10.04 |
LTC Properties Inc is a real estate investment trust. It invests in seniors housing and health care properties, mainly through ownership, sale-leasebacks, mortgage financing, joint ventures, construction financing, and structured finance solutions, including preferred equity, bridge, and mezzanine lending. The company's investment portfolio comprises several properties located throughout the USA, the majority of which are seniors housing and skilled nursing properties. The firm conducts and manages its business as two operating segments: Real Estate Investments, which generates maximum revenue, and SHOP.
Tyra Biosciences Inc is a clinical-stage biotechnology company focused on developing next-generation precision medicines for large opportunities in targeted oncology and genetically defined conditions, harnessing the power of Fibroblast Growth Factor Receptor (FGFR) biology. The company's in-house precision medicine platform, SNAP, enables rapid and precise drug design through iterative molecular SNAPshots that help to design and predict which product candidates may demonstrate the highest potency, selectivity, and tolerability in the clinic. The various drug candidates in the company's product pipeline are FGFR3, FGFR4/3, and FGFR1/2/3: three clinical-stage, novel small molecules designed to overcome the toxicity and resistance liabilities of first-generation pan-FGFR inhibitors.